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Abstract
Objectives: This study was conducted to evaluate the prognostic value of, respectively, the 6th and 7th
editions of the American Joint Committee on Cancer (AJCC) staging system for patients with resected
perihilar cholangiocarcinoma (PHC).
Methods: Patients who underwent resection of PHC between 1991 and 2012 were identified from
prospective databases at two centres. Overall survival was estimated using the Kaplan–Meier method
and compared across stage groups with the log-rank test. The concordance index and Brier score were
used to compare the prognostic accuracy of the staging systems.
Results: Data for a total of 306 patients were analysed. Staging according to the 7th edition upstaged
63% of patients in comparison with staging by the 6th edition. The log-rank P-value for both staging
systems was highly statistically significant (P < 0.001). Staging according to the 6th edition categorized
93% of patients as having stage I or II disease, whereas staging according to the 7th edition distributed
patients more equally across stages. Prognostic accuracy was similar between the staging systems: the
concordance index was 0.59 and the Brier score 0.17 for both the 6th and 7th editions. The same
prognostic accuracy was achieved using an alternative tumour–node–metastasis (TNM) stage grouping
simplified to four rather than six stage groups.
Conclusions: The 6th and 7th editions of the AJCC staging system for PHC have similar prognostic
accuracy. Other prognostic factors can potentially improve individual patient prognostication.
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Introduction
Perihilar cholangiocarcinoma (PHC) accounts for about 60% of
all cases of cholangiocarcinoma and has an annual incidence of
one to two cases per 100 000 population. It involves the occur-
rence of tumours at or near the biliary confluence, arising between
the origin of the cystic duct and the confluence of the second-
order bile ducts.1 Tumours arising distal to the origin of the cystic
duct are classified as lesions of distal cholangiocarcinoma, and
tumours that are proximal to the left and right hepatic ducts are
classified as lesions of intrahepatic cholangiocarcinoma. Patients
with PHC typically present with symptoms arising from bile duct
obstruction. Resection is the optimal treatment and facilitates a
median overall survival (OS) of about 44 months.2 Unfortunately,
at presentation the majority of patients have metastatic or
locally advanced disease and consequently do not benefit from
resection.
Several systems for staging PHC have been published. The
Bismuth classification and the Blumgart T-stage focus on deter-
mining resectability using preoperative imaging.3,4 DeOliveira
et al. recently introduced a new classification for PHC, including
both radiologic and pathologic covariates.5 This classification is
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comprehensive, but remains to be validated. The American Joint
Committee on Cancer (AJCC) staging still represents the staging
system most widely used to determine prognosis and appropriate
treatment, and to compare outcomes among centres.
In the 6th edition (2003) of the AJCC staging system, all
patients with extrahepatic bile duct tumours were covered by a
single classification.6 In the 7th edition (2010), perihilar (proxi-
mal) and distal cholangiocarcinoma were staged separately.1 Two
important changes from the 6th to 7th editions for PHC concern
the definitions of T-stage (Table 1). Firstly, invasion of the liver
parenchyma was downstaged to stage T2b in the 7th edition from
stage T3. Secondly, T4 was expanded to include the bilateral
involvement of second-order bile ducts (Bismuth 4), and the uni-
lateral involvement of second-order bile ducts and contralateral
vascular involvement.With respect to N-stage, N2 was introduced
as a new N-stage for metastases to lymph nodes beyond those in
the hepatoduodenal ligament, including the periaortic and
pericaval lymph nodes and those at the superior mesenteric artery
or the coeliac artery.
Other changes concerned the distribution of T- and N-stages
across the stage groups. Firstly, invasion beyond the bile duct wall
(T2) was upstaged from stage Ib to stage II. Secondly, invasion of
the unilateral branches of the portal vein or hepatic artery (T3)
was upstaged from stage IIa to stage IIIa. Thirdly, regional lymph
node metastasis was upstaged from stage IIb to stage IIIb.
Fourthly, stage IV was expanded to include disease of T4 (IVa) and
N2 (IVb) status, in addition to that of M1 (IVb) status.
The objective of this study was to compare the prognostic
accuracy of the 6th and 7th editions of the AJCC staging system
in patients with resected PHC. Secondly, alternative stage
distributions were evaluated to improve on the current AJCC
staging.
Materials and methods
Patient population
This study included patients for whom prospective data had been
collected in databases at two centres: the Academic Medical
Centre (AMC) in Amsterdam, the Netherlands, and the Memorial
Sloan–Kettering Cancer Center (MSKCC) in New York, USA. The
institutional review boards of each centre approved the study.
Consecutive patients with resected PHC were included. Perihilar
cholangiocarcinoma was defined as cancer arising from the
common hepatic duct (i.e. arising proximal to the origin of the
cystic duct), biliary confluence, or main hepatic ducts (left or
right) up to the confluence of the second-order bile ducts. Patients
with papillary PHC and carcinoma in situ were also included. The
study exclusion criteria excluded patients with final pathology
indicative of a diagnosis other than PHC, patients who suffered
in-hospital mortality, patients who underwent an R2 resection,
and patients submitted to re-resection after initial resection in
another hospital. Data on patient demographics, laboratory
studies, preoperative imaging, preoperative biliary drainage, type
of surgery, pathology and OS were collected.
Table 1 American Joint Committee on Cancer (AJCC) staging system by tumour–node–metastasis (TMN) stage
Stage AJCC, 6th edition AJCC, 7th edition
Tumour (T) stage
T1 Tumour confined to the bile duct Tumour confined to the bile duct, with extension up to
the muscle layer or fibrous tissue
T2 Tumour invades beyond the wall of the bile duct –
T2a – Tumour invades beyond the wall of the bile duct to
surrounding adipose tissue
T2b – Tumour invades adjacent hepatic parenchyma
T3 Tumour invades the liver, gallbladder, pancreas, and/or
unilateral branches of the PV or HA
Tumour invades unilateral branches of the PV or HA
T4 Tumour invades main PV or its branches b/l, CHA, or
other adjacent structures (such as colon, stomach,
duodenum, abdominal wall)
Tumour invades main PV or its branches b/l, CHA,
second-order bile ducts b/l, unilateral second-order
bile ducts with contralateral PV or HA involvement
Node (N) stage
N0 No regional lymph node metastasis No regional lymph node metastasis
N1 Regional lymph node metastasis: hilar (along the CBD,
cystic duct, HA, PV), coeliac, periduodenal,
peripancreatic, SMA
Regional lymph node metastasis: hilar (along CBD,
cystic duct, HA or PV)
N2 – Metastasis to periaortic, pericaval, SMA or coeliac
lymph nodes.
Metastasis (M) stage
M0 No distant metastasis No distant metastasis
M1 Distant metastasis Distant metastasis
PV, portal vein; HA, hepatic artery; CHA, common hepatic artery; SMA, superior mesenteric artery; CBD, common bile duct; b/l, bilateral.
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Patient management
Preoperative workup and patient selection for surgery were
similar in both centres. Patients typically underwent
cross-sectional imaging with computed tomography (CT) of
the chest, abdomen and pelvis and magnetic resonance
cholangiopancreatography (MRCP) of the liver at or before initial
referral, ideally prior to biliary drainage. Imaging allowed for
evaluation of distant metastases, the biliary extent of the tumour,
and involvement of the portal vein and hepatic artery. In recent
years, preoperative biliary drainage of the presumed remnant liver
was carried out percutaneously rather than endoscopically in
order to minimize the bacterial contamination of the biliary tract.
However, many patients had undergone endoscopic drainage
before referral. A brush was typically performed at the time of
preoperative biliary drainage. However, pathologic confirmation
of malignancy was not required to proceed with surgical resection.
Diagnostic laparoscopy to rule out distant metastatic disease was
performed often, but not in all patients, given the decreasing yield
as preoperative imaging improved over time.7 With some excep-
tions, patients with involvement of the main portal vein, the
portal vein bilaterally, the common hepatic artery or the hepatic
artery bilaterally were considered unresectable. Patients with
involvement of the second-order bile ducts were considered
resectable if clear margins at the segmental bile ducts were antici-
pated. Fewer than 5% of all patients underwent preoperative
portal vein embolization if the size and function of the future liver
remnant were considered to be insufficient. Fewer than 5% of all
patients underwent neoadjuvant therapy.
Staging
Table 2 presents the AJCC staging classification for both the 6th
and 7th editions. Tumour stage was determined based on macro-
scopic and microscopic evaluations of the resected specimen.
Evaluation of the biliary extent of the tumour was necessary to
determine T4 stage in the 7th edition of the AJCC staging system.
In fewer than 5% of patients, preoperative cross-sectional imaging
was used if the pathology report was insufficiently detailed to
determine the biliary extent of the tumour: isolated second-order
biliary bile ducts were considered to be involved by the tumour.
Evaluation of the vascular involvement of the tumour (portal vein
or hepatic artery) was necessary to determine stages T3 and T4
according to both editions. In fewer than 5% of all patients, preop-
erative cross-sectional imaging was used if the pathology report
was insufficiently detailed to determine vascular involvement: the
portal vein and hepatic artery were considered to be involved in
cases of occlusion, obvious narrowing or tumour abutment of
≥180 degrees.
Alternative tumour–node–metastasis stage groupings
Two regroupings of tumour–node–metastasis (TNM) stages were
compared across the 6th and 7th editions of the AJCC staging
system. A regrouping of TNM stages was recently proposed by a
Japanese multicentre study (Ebata staging).8 In this staging
system, bilateral second-order bile duct involvement (Bismuth 4)
was removed from the T4 definition. Moreover, T4N0 patients
were downstaged to stage IIIb, and TanyN1 patients were upstaged
to stage IVa.
An alternative simplified regrouping of TNM stages was evalu-
ated with only four stages: stage I represented disease that was
confined to the bile duct (T1N0); stage II represented disease that
extended beyond the bile duct (T2–4N0); stage III represented
node-positive disease (TanyN1), and stage IV represented disease
that included N2 nodes or distant metastasis (TanyN2 or
TanyNanyM1).
Statistical analyses
Statistical analyses were performed using IBM spss Statistics for
Windows Version 21.0 (IBM Corp., Armonk, NY, USA) and R (a
language and environment for statistical computing)Version 3.0.2
for Mac (R Foundation for Statistical Computing, Vienna,
Austria). Survival was measured from the date of surgery to the
date of death or date of last contact prior to 1 January 2014.
Survival probabilities were estimated using the Kaplan–Meier
method and compared with the log-rank test. Overall survival was
the primary outcome.
The concordance index and Brier score were used to compare
the staging systems.9 The concordance index is a measure of dis-
crimination used to evaluate whether a staging system can dis-
criminate between two patients at different stages of disease. It is
calculated as the probability that for a random pair of patients at
different stages of disease, the patient at the lower stage has a
longer observed survival. A concordance index of 0.5 means that
the predictive ability is no better than guessing; a concordance
index of 1 means perfect prediction. Other AJCC staging systems
were found to have a concordance index of about 0.70.10 When
stage-specific survival is consistently higher or lower than the
observed survival, this would be expected to remain undetected by
the concordance index. Therefore, the Brier score is often used in
combination with the concordance index. The Brier score is a
Table 2 American Joint Committee on Cancer (AJCC) staging
system
AJCC, 6th edition AJCC, 7th edition
Stage T N M Stage T N M
0 is 0 0 0 is 0 0
Ia 1 0 0 I 1 0 0
Ib 2 0 0 –
IIa 3 0 0 II 2 0 0
IIb 1–3 1 0 –
III 4 Any 0 IIIa 3 0 0
– – IIIb 1–3 1 0
IV Any Any 1 IVa 4 Any 0
– IVb Any 2 0
– Any Any 1
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Table 3 Characteristics of 306 patients with resected perihilar cholangiocarcinoma assessed in the present study
Covariate n All AMC (n = 133) MSKCC (n = 173)
Gender, male, n (%) 306 179 (58%) 79 (59%) 100 (58%)
Age, years, mean (range) 306 63 (30–89) 62 (30–82) 64 (34–89)
Weight loss of >5 kg, n (%) 266 169 (64%) 69 (62%) 100 (65%)
Jaundice, n (%) 303 215 (71%) 104 (80%) 111 (64%)
Preoperative bilirubin, ml/dl, mean (range) 270 3.0 (0.2–35.6) 1.2 (0.2–8.7) 4.0 (0.2–35.6)
Bismuth stage, n (%) 306
1 58 (19%) 20 (15%) 38 (22%)
2 39 (13%) 18 (14%) 21 (12%)
3a 79 (26%) 39 (29%) 40 (23%)
3b 64 (21%) 26 (20%) 38 (22%)
4 43 (14%) 18 (14%) 25 (14%)
Left or right bile duct, n (%) 23 (8%) 12 (9%) 11 (6%)
Lobar atrophy, n (%) 300
No 211 (70%) 104 (81%) 107 (63%)
Right 38 (13%) 15 (12%) 23 (13%)
Left 51 (17%) 10 (8%) 41 (24%)
Portal vein involvement, n (%) 272
No 176 (65%) 68 (67%) 108 (63%)
Right 36 (13%) 11 (11%) 25 (15%)
Left 54 (20%) 19 (19%) 35 (20%)
Main 2 (1%) 1 (1%) 1 (1%)
Bilateral 2 (1%) 2 (2%) 0
Preoperative drainage, n (%) 304
No 61 (20%) 17 (13%) 44 (25%)
PTC 51 (17%) 11 (8%) 40 (23%)
ERCP 156 (51%) 84 (64%) 72 (42%)
Both 36 (12%) 19 (15%) 17 (10%)
Type of resection, n (%) 306
Bile duct resection only 53 (17%) 21 (16%) 32 (19%)
Left hepatectomy 88 (29%) 37 (28%) 51 (30%)
Right hepatectomy 24 (8%) 8 (6%) 16 (9%)
Extended left hepatectomy 25 (8%) 15 (11%) 10 (6%)
Extended right hepatectomy 90 (29%) 32 (24%) 58 (34%)
Central hepatectomy 26 (8%) 20 (15%) 6 (3%)
Caudate resectiona, n (%) 302 137 (45%) 74 (57%) 63 (36%)
Papillary tumour, n (%) 306 57 (19%) 18 (14%) 39 (23%)
Positive margin, n (%) 306 84 (28%) 39 (29%) 45 (26%)
Differentiation, good, n (%) 297 69 (23%) 29 (23%) 40 (24%)
Lymphovascular invasion, n (%) 299 78 (26%) 24 (19%) 54 (31%)
Perineural invasion, n (%) 306 211 (69%) 91 (68%) 120 (69%)
aThe caudate resection rate is relatively low because 19% of the study population had a Bismuth 1 tumour: these patients typically did not undergo
any liver resection. Moreover, in the early 1990s, caudate resections were less commonly performed.
AMC, Academic Medical Centre (Amsterdam, the Netherlands); MSKCC, Memorial Sloan–Kettering Cancer Center (New York, NY, USA); PTC,
percutaneous transhepatic cholangiography; ERCP, endoscopic retrograde cholangiopancreatography.
HPB 1077
HPB 2014, 16, 1074–1082 © 2014 International Hepato-Pancreato-Biliary Association
measure of the average difference between observed survival and
predicted stage-specific survival. Lower Brier scores are better; a
Brier score of 0 is perfect. Other AJCC staging systems were found
to have Brier scores of about 0.16.10
Results
Patients
A total of 306 consecutive patients submitted to surgery between
1991 and 2012 were identified. These included: 133 (43.5%)
patients at AMC and 173 (56.5%) patients at MSKCC. No
patients were excluded for missing data on staging. Patient char-
acteristics are summarized in Table 3. Median OS was 40 months
(95% confidence interval: 34–46 months). A total of 103 patients
(33.7%) were censored at a median follow-up time of 38
months.
Stage transitions
Table 4 is a cross-tabulation presenting transitions for T-stages,
N-stages and AJCC stages for the 6th and 7th staging editions.
Survival across stages
Figure 1(a) and (b) presents Kaplan–Meier curves for OS for the
four main stage groups of the 6th and 7th editions. Findings of the
log-rank test for both staging systems were highly statistically
significant (P = 0.002 and P < 0.001, respectively). Figure 1(c) and
(d) demonstrates that when all sub-stages were compared, sepa-
ration of the curves further improved for both editions (P < 0.001
for both). Table 5 presents stage-specific median OS in patients
staged according to both the 6th and 7th editions of the AJCC
staging system. Figure 2a presents OS curves according to the
Ebata staging, and Fig. 2b according to the alternative staging.
Table 4 Cross-tabulation of the 6th and 7th editions of the American Joint Committee on Cancer (AJCC) staging system: (a) T-stage, (b)
N-stage and (c) AJCC stage. Each row shows how many patients at a specific 6th edition stage transitioned to other stages according to
the 7th edition. Numbers in red refer to patients who moved to a different stage from the 6th to the 7th edition
(a)
T-stage 7th edition
is 1 2a 2b 3 4 Total
6th edition is 11 11 (4%)
1 36 1 37 (12%)
2 90 5 95 (31%)
3 3 92 32 29 156 (51%)
4 7 7 (2%)
Total 11 36 93 92 32 42 306
% 4 12 30 30 10 14 100
(b)
N-stage 7th edition
0 1 2 total
6th edition 0 228 228 (75%)
1 74 4 78 (25%)
Total 228 74 4 306
% 75 24 1 100
(c)
AJCC stage 7th edition
0 I II IIIa IIIb IVa IVb total
6th edition 0 11 11 (4%)
Ia 35 1 36 (12%)
Ib 70 3 73 (24%)
IIa 63 20 17 100 (33%)
IIb 58 13 4 75 (25%)
III 7 7 (2%)
IV 4 4 (1%)
Total 11 35 133 20 58 41 8 306
% 4 11 43 7 19 13 3 100
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Figure 1 Overall survival by stage without sub-stages according to the (a) 6th edition of the American Joint Committee on Cancer (AJCC)
staging system main stage groups [data for patients with stage III (n = 7) and IV (n = 4) disease are not presented], and (b) 7th edition of the
AJCC four main stage groups. Overall survival by stage and sub-stage according to the (c) 6th edition of the AJCC staging system, including
subgroups [data for patients with stage III (n = 7) and IV (n = 4) disease are not presented], and (d) 7th edition of the AJCC staging system,
including subgroups [data for patients with stage IVb (n = 8) disease are not presented]
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Prognostic accuracy
Table 6 presents the concordance indices and Brier scores for all
evaluated staging systems. Prognostic accuracy was remarkably
similar across the AJCC staging systems. Expanding the 6th
edition of the AJCC staging system with sub-stages did not
improve prognostic accuracy; the 7th edition improved with sub-
stages but its prognostic accuracy was similar to that of the 6th
edition. The prognostic accuracy of both the Ebata staging system
and the alternative staging system was similar to that of the AJCC
staging systems.
Table 5 Stage-specific median overall survival (OS) in months according to the 6th and 7th editions of the American Joint Committee on
Cancer (AJCC) staging system. Median OS is not presented for 6th edition stages III (n = 7) and IV (n = 4). Differences in OS between the
four main stage groups of the 6th and 7th editions were highly statistically significant (log-rank P = 0.002 and P < 0.001, respectively), as
well as when sub-stages were considered (both P < 0.001)
6th edition AJCC 7th edition AJCC
n Median OS 95% CI n Median OS 95% CI
0 11 80 26–135 11 80 26–135
I 109 48 26–70 35 65 33–97
Ia 36 65 33–98 – – –
Ib 73 41 32–49 – – –
II 175 33 25–41 133 46 30–61
IIa 100 48 35–61 – – –
IIb 75 21 18–24 – – –
III – – – 78 27 22–32
IIIa – – – 20 40 25–55
IIIb – – – 58 26 19–34
IV – – – 49 24 19–28
IVa – – – 41 26 17–35
IVb – – – 8 17 3–31
Results for the main stage groupings are shown in bold.
95% CI, 95% confidence interval.
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Figure 2 Overall survival by stage in patients staged according to (a) Ebata staging [data for patients with stage IVb (n = 5) disease are not
presented], and (b) an alternative staging system [data for patients with stage IV (n = 8) disease are not presented]
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Discussion
This study compared the 6th and 7th editions of the AJCC staging
system in patients with resected PHC using prospective databases
from two centres. The log-rank P-value across all sub-stages was
highly statistically significant for both the 6th and 7th editions
(P < 0.001). Prognostic accuracy was similar for both editions,
with a concordance index of 0.59 and a Brier score of 0.17. The
same prognostic accuracy was achieved using an alternative TNM
stage grouping simplified to four rather than six stage groups
(Fig. 2b, alternative staging).
A study from Germany compared the 6th and 7th editions of
the AJCC system.11 The authors of this study analysed data for all
patients (n = 195) who underwent exploratory laparotomy for
PHC with or without resection between 1998 and 2010. A disad-
vantage of including unresected patients is that the T-stage (with
particular reference to vascular involvement and the biliary extent
of the tumour) was determined on preoperative imaging and
intraoperative assessment, without histologic verification. The
authors of the study compared P-values derived from Cox pro-
portional hazards modelling (P = 0.44 for the 6th edition and P =
0.0093 for the 7th edition) and concluded that the 7th edition
better separated the survival curves of patients with stage II and III
disease, respectively.
A study from Japan evaluated the 7th edition of the AJCC
staging system and found that patients with T4 tumours (stage
IVa) had better survival than patients with regional node-positive
disease (stage IIIb), a finding confirmed in the present study.8
They proposed a modified staging system that was considered
superior based on a higher chi-squared value.Validation using the
data in the present study found the prognostic accuracy of this
modified staging system to be similar to that of the 6th and 7th
editions of the AJCC staging system (Table 5, Ebata staging).
However, a higher proportion of patients in the Japanese series
with Bismuth 4 or involvement of the main portal vein may have
caused suboptimal validation.
The present study has several limitations. Firstly, this study is
one of the largest Western series of patients with resected PHC
(n = 306) to be reported in the literature, but its sample size is still
insufficient to allow for the drawing of definitive conclusions
about small modifications in the staging system. Secondly, this
study included only resected patients. The advantage of this is that
pathological confirmation of the TNM stage was available for all
patients. The disadvantage is that the results cannot be extrapo-
lated to patients who do not undergo resection because of distant
metastasis or locally advanced disease. Only resected patients were
included in this study because the assessment of both T-stage and
N-stage is inaccurate without microscopic evaluation of the
resected specimen. The evaluation of N-stage based on size cri-
teria on cross-sectional imaging has been shown to be very inac-
curate: only 37% of lymph nodes of >3 cm in diameter were found
to be positive.12 Thirdly, in the present series, relatively few
patients showed involvement of the main portal vein or common
hepatic artery that required vascular resection and reconstruction.
Centres around the world disagree about resectability criteria for
patients with PHC. Some centres have published higher resection
rates for patients with main or bilateral portal vein involve-
ment.13,14 Consequently, OS in stage IV patients in the present
study differs from that in stage IV patients reported in studies that
include more stage T4 patients.
Historically, the AJCC staging is based mainly on the anatomic
extent of the tumour. Although non-anatomic factors have been
introduced into the staging of some cancers (e.g. mitotic rate in
melanoma), with reference to PHC, the 6th and 7th editions of the
AJCC staging system adhered to the anatomic extent of the
tumour, as in all other hepatobiliary and pancreatic cancers.1
Several series of patients with PHC have identified independent
prognostic factors, such as margin status, tumour differentiation
and perineural invasion.14 Future research should investigate
whether a combination of AJCC staging and non-anatomic inde-
pendent prognostic factors can further improve individual patient
prognostication.
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